0.07
-4.23%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genetic Signatures
Its shares trade on ASX under the ticker GSS.AX. It has been listed since 31 March 2015. In the fiscal year to 30 June 2026, it reported revenue of A$14.5m and a net loss of A$14.0m. At that date it held total assets of A$38.5m and shareholders' equity of A$35.7m.
Genetic Signatures Ltd. is a molecular diagnostics company, which focuses on the development of real-time PCR based products for the routine detection of infectious diseases. The Company’s principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. The company designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 31 Mar 2015
- Website
- geneticsignatures.com/au ↗
Leadership
Pay as last reported
- Mrs. Caroline WaldronNon-Executive Chairman of the BoardA$8,750
- Mr. Allison RossiterChief Executive Officer
- Mr. Karl PechmannChief Financial Officer, Joint Company Secretary
- Mr. Michael AicherExecutive Director - US Operations, since 2014A$178,907
- Mr. Michael SapountzisJoint Company Secretary
- Dr. Neil GunnNon-Executive Director, since 2021A$169,363
- Dr. Jenny HarryNon-Executive Director
- Ms. Anne LockwoodNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection in Australia.
- The MDx 3base platform technology enables high-volume hospitals to screen pathogens rapidly.
- EasyScreen brand offers specific detection kits for enteric, STI, and viral meningitis pathogens.
Weaknesses
- The company focuses solely on molecular diagnostics without expanding into other health sectors.
- Genetic Signatures Ltd. has no presence in international markets beyond Australia.
- Its business model relies on a single platform technology, 3base, for commercialization.
Opportunities
- Expanding the EasyScreen product line to include more infectious disease detection kits.
- Growing demand for rapid diagnostic tools in Australian healthcare facilities.
- Increasing adoption of molecular diagnostics in pathology laboratories across Australia.
Threats
- Competition from established diagnostic companies in the Australian market.
- Regulatory changes affecting molecular diagnostics in the Health Care sector.
- Economic downturns impacting healthcare spending in Australia.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.